STX1A and hemolytic-uremic syndrome: Such protective efficacy of chimeric anti-Stx1 and anti-Stx2 monoclonal antibodies has been demonstrated shortly afterwards, which could be used therapeutically for the prevention or treatment early in the development of HUS [484].